News    Venture Summit West to Showcase Matrix-Bio, A Leader in Metabolomics-Based Cancer Diagnostics

Venture Summit West to Showcase Matrix-Bio, A Leader in Metabolomics-Based Cancer Diagnostics

Posted January 31, 2014 by Melanie Lux • No Comments

FORT WAYNE, Ind., February 3, 2014 – – Matrix-Bio, Inc., a leader in the field of cancer diagnostics using metabolite profiling, is a featured startup company at the Second Annual Venture Summit West on February 13 in Mountain View, California. Matrix-Bio is seeking investment for a new colon cancer-monitoring test, which uses the company’s VeraMarker™ metabolite profiling technology platform to accurately detect the recurrence of colon cancer months before current diagnostics tests.

Sponsored by Young Startup Ventures, Venture Summit West will showcase more than 50 emerging-growth entrepreneurial companies—including Matrix-Bio—from the life sciences, technology, education technologies and clean-tech sectors. More than 40 top tier VCs and angel investors will be in attendance.

Matrix-Bio heads into Venture Summit West with substantial momentum. In 2013, Matrix-Bio signed a global licensing agreement with Quest Diagnostics for the development of a clinical lab-developed blood test using metabolite profiling to detect breast cancer recurrence (BCR). A commercial launch of the BCR test, which offers oncologists a new, highly accurate diagnostic tool, is anticipated in 2015.

Matrix-Bio is now developing a suite of colon cancer tests, initially focusing on recurrence monitoring. The market for colon cancer monitoring tests is significant: three million CEA tests (the current test which often yields false positives or detects cancer recurrence late) are performed each year with an estimated total market of $450 million. Colon cancer is the most preventable, yet least prevented cancer. It also has a high rate of reccurrence.

As part of his pitch at Venture Summit West, Matrix-Bio CEO Eric Beier will explain how the company’s VeraMarker™ metabolite profiling technology platform identifies the unique metabolite signature of cancer cells in blood serum samples, supporting early, more accurate cancer detection.

About Matrix-Bio, Inc.
Matrix-Bio, Inc. is focused on the development and commercialization of advanced metabolite profile blood tests for early cancer detection, recurrence detection, and therapy monitoring that offer greater accuracy, convenience, and lower cost than current testing methodologies. Matrix-Bio is currently developing a portfolio of colon cancer diagnostic tests. Visit

No Comments

No comments yet.

Sorry, the comment form is closed at this time.


If you have questions about Matrix-Bio’s early liver cancer detection test or about our investing and partnership opportunities, please contact:

Eric Beier, MD, MBA